试验方法提交指南Guidelines For The Submission Of Protocol Of Analysis

2010-07-03 MedSci原创 MedSci原创

Guidelines For The Submission Of Protocol Of Analysis I.   General Requirements 1. The Protocol of analysis must&nb

Guidelines For The Submission Of Protocol Of Analysis

I.   General Requirements

1. The Protocol of analysis must be in a standard format that contains information as stated below:-
a. Product name
b. Name and address of manufacturer
c. Name, signature and designation of authorized person
d. Effective date
e. Review date

2. Protocol of analysis must consist of all test methods and specifications that are carried out by the manufacturer. Standard pharmacopoeias, for example, BP/USP can be used as references. The tests and specifications in the pharmacopeias are the minimum requirements.

3. Photocopies of methods/ methods directly copied from pharmacopoeias are not acceptable. Manufacturers can use methods from those standard references but must have their own written and detailed procedure. 

4. Manufacturers must confirm that all test methods in their protocol of analysis perform as expected. Copies of chromatograms (HPLC/GC/TLC), UV spectrum etc must be submitted together with the protocol of analysis.

5. Protocol of analysis must be properly ordered with proper numbering for all tests and specifications..

6. All references stated in the protocol of analysis must be submitted and clearly labeled.

7. Protocol of analysis submitted must be in either Bahasa Malaysia or English. Protocol of analysis in other languages will be rejected.

8. An authorized copy of latest certificate of analysis for the product concern must be submitted with the protocol of analysis.


II. Specific Requirements

1. Identification test
a. List of equipment and apparatus required. 
b. List of chemical / reagents
c. Preparation of sample and standard solutions.
d. Details of method and procedures.
e. Specification and acceptance criteria
2. Physical test (friability, uniformity of weight, pH, viscosity, etc).
a. List of equipment required together with test parameters.
b. Sample preparation (if any).
c. Specification and acceptance criteria

3. Disintegration test
a. Equipment required
b. Test parameters
c. Test medium
d. Specification
4. Dissolution test
a. Equipment and apparatus required.
b. List of chemical / reagents required
c. Test parameters i.e. type and volume of dissolution medium, rotation rate, temperature of solution and time.
d. Preparation of dissolution medium, preparation of sample and standard solution (if any), etc.
e. Type and method of analysis (HPLC, UV, etc) and test procedures. For example, if HPLC method is used, test method has to include the preparation of mobile phase, brand and type of column used, run time, detector used (UV, RI, etc), injection volume, system suitability test and other parameters.
f. Typical chromatograms / UV spectrum for sample & standard solution, system suitability etc.
g. Complete formula for calculation. For example, ‘slow release’ products calculation must include quantity of active substance in the medium volume which have been taken out for analysis.
h. Test specification
5. Impurities / degradation / purity test
a. List of equipment and apparatus required,
b. List of chemical and reagents required.
c. Preparation of sample and standard solutions.
d. Detailed method and procedures
e. Complete formula for calculation.
f. Typical chromatogram of system suitability test, sample & standard solutions if applicable.
g. Specification / acceptance criteria.
6. Assay and uniformity of content
a. List of equipment and apparatus required,
b. List of chemical and reagents required.
c. Preparation of sample and standard solution 
d. Detailed method and procedures
e. Complete formula for calculation.
f. Typical chromatogram/spectrum of system suitability test, sample & standard solutions if applicable.
g. Specification / acceptance criteria.
7. Pyrogen / abnormal toxicity test
a. List of equipment, apparatus, glassware and reagents required.
b. Preparation of sample solution and injection dose.
c. Test method & procedure.
d. Test interpretation
e. Test specification
8. Bacterial Endotoxins Test (LAL)
a. List of apparatus, glassware and reagents required.
b. Preparation of standard solution, LAL reagent/substrate and sample.
c. Determination of MVD (Maximum Valid Dilution ) and endotoxin limit.
d. Detailed test procedure.
e. Calculation and interpretation of test result
f. Test specifications.
9. Microbial Limit Test
9.1 Determination of microbial contamination test
i. List of apparatus and culture required.
ii. Preparation of test medium and growth promotion test.
iii. Sample preparation including method for neutralizing of preservatives for samples that contain preservatives.
iv. Complete test procedure by ‘surface spread’ for bacteria and ‘pour plate’ for fungi.
v. Colony counting
vi. Specification and acceptance criteria
9.2 Test for specified microorganisms and total viable aerobic count
i. List of apparatus and culture required.
ii. Preparation of test medium and growth promotion test.
iii. Sample preparation including method for neutralizing of preservatives for samples that contain preservatives.
iv. Complete test procedure for each of specific microorganism involved.
v. Observation on colonies presence.
vi. Specifications and acceptance criteria.
10. Sterility test
a. List of apparatus required.
b. List of biological and chemical substance required:-
i. Culture medium
ii. List of rinsing solution, buffer solution and diluent
iii. Neutralizing agent (if any)
iv. List of specific type cultures required
c. Method used (e.g. membrane filtration method, direct inoculation, etc)
d. Method of preparation of the following solutions/materials:-
i. Culture medium (e.g. Fluid Thioglycollate Medium and Soyabean Casein Digest Medium).
ii. Rinsing solution, buffer solution and diluents.
iii. Neutralizing agent (if any).
iv. Microorganism culture
 e. Growth promotion test for  medium used in sterility testing (specific aerobes, anaerobes and fungi).
 f. Preparation of sample solution (including neutralizing procedure of antimicrobial agent for antibiotic samples and samples which contain preservatives).
 g. Complete test procedure for sterility test.
 h. Specifications and acceptance criteria.
 i. Validation procedure & validation data (if applicable).


11. Microbiology assay
a. List of apparatus required.
b. List of biological and chemical substances required.
c. Procedure for the preparation of following solutions/substances:-
i, Culture mediums
ii. Rinsing solutions.
iii. Buffer solutions
iv. Diluents
v. Microorganism culture used in assay
d. Test method (e.g. agar diffusion, turbidimetric, randomized block, dose, etc)
e. Test procedure
i. Preparations of solutions containing antimicrobial agents which may be present in the sample to be tested (if applicable).
ii. Preparation of standard solutions (including any steps to counteract the  antimicrobial properties of any preservatives, etc present in the sample)
iii. Preparation of test solutions (including any steps to neutralize the  antimicrobial properties of any preservatives, etc present in the sample)
iv. Dilution schemes for test and standard solutions.
v. Application of test & standard solutions (volume,  latin squares, etc)
vi. Incubation temperature & time
vii. Procurement of test data.
f. Complete calculation for the test including ANOVA tablet and other data showing validity of test results.
g. Specifications and acceptance criteria.

Guideline For Submission Of  Samples To The Drug Analysis Division For Laboratory Testing.

1. Introduction
This guideline is written for the purpose of informing applicants on the Drug Analysis Division requirements when receiving samples for laboratory testing as part of the registration process. Applicants are required to comply with these requirements as their samples can be rejected if they fail to meet any of these requirements

2. Requirements
a. Applicants must make appointment with the Laboratory Services Unit for the submission of registration samples for laboratory testing.
b. Requirements for samples:-
A. Pharmaceuticals
i. Samples submitted must be in their original packaging & labeling.
ii. Quantity of samples submitted must be in accordance with the quantity requested for in the protocol of analysis evaluation report. 
iii. Samples submitted must be from the same manufacturing premise as that stated in the application for registration.
iv. Samples submitted must have an expiry date of least one (1) year from the date of submission.
v. An official certificate of analysis from the manufacturer for the same batch of sample must be submitted with the sample.

B. Traditional Products

i. Samples submitted must be in their original packaging & labeling.
ii. Quantity of samples submitted must be in accordance with the quantity requested. A minimum of 4 separate containers with total contents not less than 50gm. 
iii. Samples submitted must be from the same manufacturing premise as that stated in the application for registration.
iv. Samples submitted must have an expiry date of least one (1) year from the date of submission

c. Requirements for reference standards (Pharmaceuticals only)

i. The type & quantity of reference standards submitted must be in accordance with the type & quantity requested for in the protocol of analysis evaluation report.
ii. Reference standards submitted must have an expiry date of least one (1) year from the date of submission. In special situations, an expiry date of not less than six (6) months can be accepted.
iii. All reference standards must be accompanied by an official certificate of analysis for the same batch with the stated purity (as is, dried, anhydrous etc) and all other relevant information (water content, loss on drying etc).
iv. All reference standards must be properly labeled with name, batch number, purity and expiry date.
v. All reference standards must be submitted in small sealed air-tight amber glass containers.

d. Other materials such as HPLC columns, reagents, etc requested for in the protocol of evaluation report must be submitted.

e. For imported products, the original import permit endorsed by the enforcement officer at the entry point must be submitted. For locally manufactured products, a copy of the batch manufacturing record (BMR) must be submitted.

3. Appeal for retesting
a. Applicants are allowed only one (1) appeal for any sample that fails laboratory testing in the Drug Analysis Division subjected to approval by the Deputy Director, Drug Analysis Division.
b. Appeal for retesting must be submitted through the on-line registration system to the Deputy Director, Drug Analysis Division within 30 days from the date the results is sent to the applicant. No appeals will be entertained after 30 days as the on-line registration system does not allow appeal for retesting after the results of the laboratory testing is release to BPKP (Product evaluation & Safety Division). Results of laboratory tests of failed samples are only release to BPKP 30 days after the applicants are informed of the results to enable them to submit their appeal.
c. Appeals for retesting must be substantiated with reasons for the failure as well as corrective actions taken to overcame the failure. The decision to approve or reject the appeal lies with the Deputy Director, Drug Analysis Division.
d. If the appeal for retesting is approved, the applicant will be requested to submit the sample together with all reference standards & other materials requested for in the original protocol of analysis evaluation report. This sample will be treated as a normal registration sample and the applicant will be required to pay for all tests conducted on this sample.
e. If there is no appeal within 30 days or if the appeal is rejected , the results of the original tests is final and the sample will be considered as failed laboratory testing.
f. The results of the retested sample is final and there is no provision for a second appeal.

Guideline For Submission Of Analytical Method Validation
Documents.

2. Introduction

The requirements for the submission of the analytical method validation data and documents by the industry to the Drug Analysis Division, National Pharmaceutical Control Bureau (NPCB) are presented in this guide. 

All the analytical validation done by the industry should be in accordance to ASEAN and ICH Technical Requirements Guidance Documents specifically:-
 
Q2A:   Text on validation of analytical procedures, 1994
Q2B     Validation of analytical procedure: methodology, 1996

3. Requirements

The industry is required to submit the following documents for evaluation by NPCB:-

a. Analytical method protocol for the testing of the raw materials (only the active pharmaceutical ingredients (API) and preservatives if any). This should include the specifications and certificate of analysis. All analytical test procedures where possible should be in accordance with the official monograph of that ingredient in the latest edition of the official pharmacopoeia such as British Pharmacopoeia, United States Pharmacopoeia and WHO.

b. Analytical method validation protocol for the finished product. The protocol of analysis should be in accordance with NPCB’s guidelines for the submission of protocol of analysis.

c. Protocol for the analytical method validation procedure carried out on the finished product. This procedure should include all details about the validation process including preparation of all solutions used – standards, samples, placebo etc, detection methods, test conditions, equipment used, statistical analysis & evaluation, calculations etc. 

Types of analytical procedures to be validated includes:-
i. Identification tests
ii. Quantitative tests for impurities content
iii. Limit tests for control of impurities
iv. Quantitative tests of the active ingredient in the sample
v. Pyrogen / Bacterial endotoxin test
vi. Sterility test

A brief description of the type of tests considered in this document is provided below:-

Identification tests are intended to ensure the identity of an active ingredient in the sample. This is normally achieved by comparison of a property of the sample e.g. spectrum, chromatographic behavior, chemical reactivity, etc) to that of a reference standard. 

Testing for impurities can be either a quantitative test or a limit test for the impurity in the sample. Either tests is intended to accurately reflect the purity characteristics of the sample. Different validation characteristics are required for a quantitative test than for a limit test. 
Assay procedures are intended to measure the content of active pharmaceutical ingredient present in a given sample. The analytical data submitted must be able to support the claim that the analytical method employed has been validated. 

Pyrogen Test and Limulus Amebocyte Lysate Test - 
Relevant validation data for pyrogen test and Limulus Amebocyte Lysate Test include product independent data such as equipment validation, validation of temperature system, lysate sensitivity and product dependent validation data such as inhibition / enhancement studies and validation for routine LAL tests according to the type of LAL test method employed eg. Gel Clot method, quantitative end point method or quantitative kinetic method. 

Sterility testing applied to products that are required to be sterile. A satisfactory result indicates that no contaminating microorganism has been found in the sample examined in the condition of the test. For sterility testing it is imperative that the testing procedure adopted by the manufacturers include all aspects of validation of the testing method including the precautions against microbial contamination.

d. Complete set of data obtained from the validation process. These include all raw data such as weights used, chromatograms, tabulated sets of value as well as graphs, statistical analysis & evaluation, calculations & formulae etc. Summary of data will not be accepted. Acceptance criteria for each characteristic/ parameter should also be submitted. For products tested using analytical methods described  in official pharmacopeias, users are not required to validate accuracy and reliability of these methods, but must submit data verifying their suitability under actual conditions of use.

e. Certificate of analysis of three (3) recent batches of the finished product 

f. Certificate of analysis for one batch of API used in the product.

g. Summary on the validation process together with conclusion reached.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1649405, encodeId=c8fe16494055e, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Fri Mar 18 10:49:00 CST 2011, time=2011-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700000, encodeId=4c8c1e000007e, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Fri Aug 06 02:49:00 CST 2010, time=2010-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633276, encodeId=190a16332e661, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Nov 27 18:49:00 CST 2010, time=2010-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634913, encodeId=0b9016349137c, content=<a href='/topic/show?id=c23314e6733' target=_blank style='color:#2F92EE;'>#protocol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14767, encryptionId=c23314e6733, topicName=protocol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63bb22340010, createdName=12498561m39(暂无昵称), createdTime=Fri Jul 16 03:49:00 CST 2010, time=2010-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068350, encodeId=f8dd20683506f, content=<a href='/topic/show?id=25de11958df' target=_blank style='color:#2F92EE;'>#MISSION#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11958, encryptionId=25de11958df, topicName=MISSION)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sat Dec 18 19:49:00 CST 2010, time=2010-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601649, encodeId=599216016492a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jul 05 13:49:00 CST 2010, time=2010-07-05, status=1, ipAttribution=)]
    2011-03-18 nymo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1649405, encodeId=c8fe16494055e, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Fri Mar 18 10:49:00 CST 2011, time=2011-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700000, encodeId=4c8c1e000007e, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Fri Aug 06 02:49:00 CST 2010, time=2010-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633276, encodeId=190a16332e661, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Nov 27 18:49:00 CST 2010, time=2010-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634913, encodeId=0b9016349137c, content=<a href='/topic/show?id=c23314e6733' target=_blank style='color:#2F92EE;'>#protocol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14767, encryptionId=c23314e6733, topicName=protocol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63bb22340010, createdName=12498561m39(暂无昵称), createdTime=Fri Jul 16 03:49:00 CST 2010, time=2010-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068350, encodeId=f8dd20683506f, content=<a href='/topic/show?id=25de11958df' target=_blank style='color:#2F92EE;'>#MISSION#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11958, encryptionId=25de11958df, topicName=MISSION)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sat Dec 18 19:49:00 CST 2010, time=2010-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601649, encodeId=599216016492a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jul 05 13:49:00 CST 2010, time=2010-07-05, status=1, ipAttribution=)]
    2010-08-06 经常头晕
  3. [GetPortalCommentsPageByObjectIdResponse(id=1649405, encodeId=c8fe16494055e, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Fri Mar 18 10:49:00 CST 2011, time=2011-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700000, encodeId=4c8c1e000007e, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Fri Aug 06 02:49:00 CST 2010, time=2010-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633276, encodeId=190a16332e661, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Nov 27 18:49:00 CST 2010, time=2010-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634913, encodeId=0b9016349137c, content=<a href='/topic/show?id=c23314e6733' target=_blank style='color:#2F92EE;'>#protocol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14767, encryptionId=c23314e6733, topicName=protocol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63bb22340010, createdName=12498561m39(暂无昵称), createdTime=Fri Jul 16 03:49:00 CST 2010, time=2010-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068350, encodeId=f8dd20683506f, content=<a href='/topic/show?id=25de11958df' target=_blank style='color:#2F92EE;'>#MISSION#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11958, encryptionId=25de11958df, topicName=MISSION)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sat Dec 18 19:49:00 CST 2010, time=2010-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601649, encodeId=599216016492a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jul 05 13:49:00 CST 2010, time=2010-07-05, status=1, ipAttribution=)]
    2010-11-27 AspirantSuo
  4. [GetPortalCommentsPageByObjectIdResponse(id=1649405, encodeId=c8fe16494055e, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Fri Mar 18 10:49:00 CST 2011, time=2011-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700000, encodeId=4c8c1e000007e, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Fri Aug 06 02:49:00 CST 2010, time=2010-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633276, encodeId=190a16332e661, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Nov 27 18:49:00 CST 2010, time=2010-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634913, encodeId=0b9016349137c, content=<a href='/topic/show?id=c23314e6733' target=_blank style='color:#2F92EE;'>#protocol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14767, encryptionId=c23314e6733, topicName=protocol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63bb22340010, createdName=12498561m39(暂无昵称), createdTime=Fri Jul 16 03:49:00 CST 2010, time=2010-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068350, encodeId=f8dd20683506f, content=<a href='/topic/show?id=25de11958df' target=_blank style='color:#2F92EE;'>#MISSION#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11958, encryptionId=25de11958df, topicName=MISSION)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sat Dec 18 19:49:00 CST 2010, time=2010-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601649, encodeId=599216016492a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jul 05 13:49:00 CST 2010, time=2010-07-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1649405, encodeId=c8fe16494055e, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Fri Mar 18 10:49:00 CST 2011, time=2011-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700000, encodeId=4c8c1e000007e, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Fri Aug 06 02:49:00 CST 2010, time=2010-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633276, encodeId=190a16332e661, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Nov 27 18:49:00 CST 2010, time=2010-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634913, encodeId=0b9016349137c, content=<a href='/topic/show?id=c23314e6733' target=_blank style='color:#2F92EE;'>#protocol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14767, encryptionId=c23314e6733, topicName=protocol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63bb22340010, createdName=12498561m39(暂无昵称), createdTime=Fri Jul 16 03:49:00 CST 2010, time=2010-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068350, encodeId=f8dd20683506f, content=<a href='/topic/show?id=25de11958df' target=_blank style='color:#2F92EE;'>#MISSION#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11958, encryptionId=25de11958df, topicName=MISSION)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sat Dec 18 19:49:00 CST 2010, time=2010-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601649, encodeId=599216016492a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jul 05 13:49:00 CST 2010, time=2010-07-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1649405, encodeId=c8fe16494055e, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Fri Mar 18 10:49:00 CST 2011, time=2011-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700000, encodeId=4c8c1e000007e, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Fri Aug 06 02:49:00 CST 2010, time=2010-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633276, encodeId=190a16332e661, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Nov 27 18:49:00 CST 2010, time=2010-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634913, encodeId=0b9016349137c, content=<a href='/topic/show?id=c23314e6733' target=_blank style='color:#2F92EE;'>#protocol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14767, encryptionId=c23314e6733, topicName=protocol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63bb22340010, createdName=12498561m39(暂无昵称), createdTime=Fri Jul 16 03:49:00 CST 2010, time=2010-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068350, encodeId=f8dd20683506f, content=<a href='/topic/show?id=25de11958df' target=_blank style='color:#2F92EE;'>#MISSION#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11958, encryptionId=25de11958df, topicName=MISSION)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sat Dec 18 19:49:00 CST 2010, time=2010-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601649, encodeId=599216016492a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jul 05 13:49:00 CST 2010, time=2010-07-05, status=1, ipAttribution=)]
    2010-07-05 sunylz